Menopause
Conditions
Keywords
Menopause; Postmenopause; Estrogen; Hormone Therapy
Brief summary
To determine whether treatment with ESTRATEST® Tablets is superior to treatment with esterified estrogens tablets
Interventions
ESTRATEST® administered orally QD
Esterified estrogens 1.25 mg administered orally QD
Sponsors
Study design
Eligibility
Inclusion criteria
Hysterectomized, menopausal women between the ages of 30 and 65 years of age (inclusive) with symptoms of estrogen and/or androgen deficiency not currently controlled by estrogen therapy as determined by patient report and the Investigator's clinical judgement
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in the total score of the Menopause Rating Scale (MRS) | 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in the domain and individual item scores of the MRS | 12 weeks |
| Change from baseline in the domain scores of the MENQOL | monthly for 3 months |
| Comparison of changes in hormone levels and correlation with changes in the MRS | 12 weeks |
Countries
United States